CJC-1295 and Fat Loss: What Has Been Studied
What the research covers
No published human trial was found that tested CJC-1295 for fat loss. One trial in people with HIV and belly fat was stopped and has no posted results. CJC-1295 is a lab-made form of GHRH, a hormone that drives the release of growth hormone (GH). After a shot, it binds to albumin, a blood protein, so it lasts much longer than natural GHRH.
That phase 2 trial compared a low dose, a high dose and placebo for 12 weeks. It was open to adults aged 18 to 65 with HIV and fat stored around the organs. The registry lists it as terminated, with a 2006 end date and no results posted. No journal paper reporting its results was found.
Two trials tested it against placebo in healthy adults aged 21 to 61. The shots went under the skin. The trials ran for 28 and 49 days. One shot raised GH levels 2 to 10 times for 6 days or more. IGF-I levels rose 1.5 to 3 times for 9 to 11 days. No serious adverse reactions were reported. These studies measured hormone levels and safety, not body changes.
In a rodent (mouse) study, young animals born without their own GHRH got CJC-1295 for 5 weeks. Their lean mass and fat under the skin were normal for their size. A PubMed search on 27 September 2026 found no human result for CJC-1295 and body fat.
Sources
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab (2006). PMID 16352683 doi:10.1210/jc.2005-1536
- Ionescu M, Frohman LA Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab (2006). PMID 17018654 doi:10.1210/jc.2006-1702
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab (2006). PMID 16822960 doi:10.1152/ajpendo.00201.2006
Frequently Asked Questions
Has CJC-1295 been tested for fat loss in humans?
What was the CJC-1295 trial in people with HIV?
What did the human studies of CJC-1295 find?
Did the animal study look at body fat?
More CJC-1295 research
Deep dives on CJC-1295
- Best Peptides for Injury Recovery: What the Evidence ShowsBest peptides for injury recovery, weighed on the evidence: what BPC-157, TB-500, GHK-Cu and four others were studied in, plus FDA's legal record in 2026.
- Thymosin Alpha 1 Peptide: Benefits, Dosage and SafetyThymosin alpha 1 peptide explained: how it works, what the trials found, the doses they used, its side effects, and where it stands with the FDA in 2026.
- BPC-157 and TB-500: What the Wolverine Stack Research ShowsBPC-157 and TB-500 (Wolverine stack): no study tested the pair. See the doses the FDA reports from human studies, what was tried together and the safety record.
- How to Reconstitute Peptides: Diluents, Maths and StorageHow to reconstitute peptides, from primary sources: the diluents an FDA label names, the concentration maths, what damages a peptide, and storage figures.
This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice.
Get the weekly UB newsletter
One email every Friday: new protocols, research breakdowns, and tactical guides. No spam. Unsubscribe anytime.